Glenn Reicin

Glenn Reicin joined Alladapt as Chief Financial Officer in June 2021. His role was expanded to include the position of Chief Operating Officer in 2023, in addition to his responsibilities as Chief Financial Officer. Prior to Alladapt Mr. Reicin was Chief Financial Officer at Sigilon Therapeutics, Inc., a provider of novel treatments for a range of chronic diseases where he "quarterbacked" the company's crossover financing and public offering. From 2013 to May 2019, Mr. Reicin served as President of Greyrock Biomedical Advisors, which provided a range of deal sourcing, valuation, due diligence and management consulting services for companies in the healthcare space. Most notably, he designed and implemented a strategy for PDL Biopharma to ensure the profitability of the company after a 2016 patent and corresponding royalty expired. Previously, in 2013, he served as an Executive-in-Resident at Covidien and from 2008 to 2012 as Managing Director at Skyline Ventures. At Skyline Ventures, he served as an active board member at a number of biotech firms. He started his career at Morgan Stanley where he became a Managing Director in equity research covering medical technology. His sell-side career spanned 18 years, including 15 years as a top-three ranked analyst and six consecutive years in the top spot.

Mr. Reicin holds an M.B.A. from Harvard Business School and B.A. from Brandeis University.